S. Meadows–Shropshire

2.9k total citations · 1 hit paper
16 papers, 768 citations indexed

About

S. Meadows–Shropshire is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, S. Meadows–Shropshire has authored 16 papers receiving a total of 768 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in S. Meadows–Shropshire's work include Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). S. Meadows–Shropshire is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). S. Meadows–Shropshire collaborates with scholars based in United States, Spain and China. S. Meadows–Shropshire's co-authors include Jan Hillson, Shun‐le Chen, Tien‐Tsai Cheng, Frédéric Houssiau, Joan T. Merrill, Kathy Nicholls, Richard Furie, Rubén Burgos‐Vargas, Abdel Saci and Arlene O. Siefker‐Radtke and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Annals of the Rheumatic Diseases.

In The Last Decade

S. Meadows–Shropshire

15 papers receiving 763 citations

Hit Papers

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant... 2023 2026 2024 2025 2023 20 40 60
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
    2023 67 citations Tina Cascone, Mark M. Awad et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Meadows–Shropshire United States 10 364 226 221 211 210 16 768
Jean Tayar United States 10 453 1.2× 138 0.6× 163 0.7× 55 0.3× 231 1.1× 30 846
Matt Truman Australia 12 269 0.7× 393 1.7× 51 0.2× 36 0.2× 78 0.4× 25 632
Daniel Tsai United States 5 206 0.6× 18 0.1× 153 0.7× 99 0.5× 119 0.6× 11 510
Shefali Agrawal United States 14 351 1.0× 183 0.8× 82 0.4× 337 1.6× 52 0.2× 29 807
Carl Millward United States 12 294 0.8× 132 0.6× 19 0.1× 114 0.5× 72 0.3× 28 624
Joo-Seop Chung South Korea 14 211 0.6× 106 0.5× 200 0.9× 49 0.2× 13 0.1× 46 690
Patricia B. Lehane United Kingdom 9 114 0.3× 88 0.4× 219 1.0× 37 0.2× 368 1.8× 20 812
Jörg Neuweiler Switzerland 12 113 0.3× 100 0.4× 45 0.2× 111 0.5× 47 0.2× 15 477
Suzanne Wilhelmus Netherlands 9 38 0.1× 118 0.5× 505 2.3× 32 0.2× 733 3.5× 16 1.0k
Keijiro Kiyoshima Japan 14 151 0.4× 467 2.1× 51 0.2× 290 1.4× 106 0.5× 41 850

Countries citing papers authored by S. Meadows–Shropshire

Since Specialization
Citations

This map shows the geographic impact of S. Meadows–Shropshire's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Meadows–Shropshire with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Meadows–Shropshire more than expected).

Fields of papers citing papers by S. Meadows–Shropshire

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Meadows–Shropshire. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Meadows–Shropshire. The network helps show where S. Meadows–Shropshire may publish in the future.

Co-authorship network of co-authors of S. Meadows–Shropshire

This figure shows the co-authorship network connecting the top 25 collaborators of S. Meadows–Shropshire. A scholar is included among the top collaborators of S. Meadows–Shropshire based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Meadows–Shropshire. S. Meadows–Shropshire is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Cascone, Tina, Mark M. Awad, Jonathan Spicer, et al.. (2025). Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T.. Journal of Clinical Oncology. 43(17_suppl). 4 indexed citations
2.
Awad, Mark M., Tina Cascone, Jonathan Spicer, et al.. (2024). LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study. ESMO Open. 9. 102985–102985. 2 indexed citations
3.
Forde, Patrick M., Solange Peters, S. Meadows–Shropshire, et al.. (2024). PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816. Journal of Thoracic Oncology. 19(10). S2–S2. 14 indexed citations
4.
5.
Cascone, Tina, Mark M. Awad, Jie He, et al.. (2023). LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Annals of Oncology. 34. S1295–S1295. 67 indexed citations breakdown →
6.
Provencio, Mariano, Patrick M. Forde, C. Wang, et al.. (2023). LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression. Annals of Oncology. 34. S1298–S1299. 13 indexed citations
7.
8.
9.
10.
Reck, Martin, Tudor–Eliade Ciuleanu, Manuel Cobo, et al.. (2020). Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.. Journal of Clinical Oncology. 38(15_suppl). 9501–9501. 101 indexed citations
11.
Sharma, Padmanee, Arlene O. Siefker‐Radtke, Filippo de Braud, et al.. (2019). Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. Journal of Clinical Oncology. 37(19). 1608–1616. 178 indexed citations
12.
13.
Klintmalm, Göran B., Sandy Feng, John R. Lake, et al.. (2014). Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study. American Journal of Transplantation. 14(8). 1817–1827. 101 indexed citations
14.
Furie, Richard, Kathy Nicholls, Tien‐Tsai Cheng, et al.. (2013). Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study. Arthritis & Rheumatology. 66(2). 379–389. 249 indexed citations
15.
Wofsy, David, S. Meadows–Shropshire, Jan Hillson, & Betty Diamond. (2012). SAT0189 Comparative analysis of alternative outcome measures for use in lupus nephritis trials. Annals of the Rheumatic Diseases. 71. 535–535. 1 indexed citations
16.
Furie, Richard, Kathy Nicholls, Tien‐Tsai Cheng, et al.. (2012). SAT0185 Efficacy and safety of abatacept in lupus nephritis. Annals of the Rheumatic Diseases. 71. 534–534. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean Tayar Breakdown of academic impact, for papers by Matt Truman Breakdown of academic impact, for papers by Daniel Tsai Breakdown of academic impact, for papers by Shefali Agrawal Breakdown of academic impact, for papers by Carl Millward Breakdown of academic impact, for papers by Joo-Seop Chung Breakdown of academic impact, for papers by Patricia B. Lehane Breakdown of academic impact, for papers by Jörg Neuweiler Breakdown of academic impact, for papers by Suzanne Wilhelmus Breakdown of academic impact, for papers by Keijiro Kiyoshima
Rankless by CCL
2026